Future studies should investigate the association between nm23-H1 binding and responses to CML therapies, and aim to determine the nature of the nm23-H1 receptor in CML, which may provide a novel target for adjunctive therapies. The gene discussed is NME1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.